Reta 30 mg
ShippingTracked, dispatched to EU and non-EU
Dispatched same working dayOn orders paid before 2:00 PM
Customs & importRules vary by country — check yours before ordering
Real supportWhatsApp & email

Reta 30 mg

Retatrutide (Reta) · Peptide

€229.95per unit
Choose variant
Reta 30 mg 1 × €229.95
€229.95
Offer saving
Shipping tracked
Calculated at checkout
Total before delivery
€229.95
Product details

Reta 30 mg

Reta is the product name used here for retatrutide (LY3437943), an investigational synthetic peptide studied for activity at the GLP-1, GIP and glucagon receptors.

References

  1. 1Research use

    Supplied for laboratory research only. Not for human or veterinary use, consumption or self-administration.

  2. 2Receipt & transport

    Inspect the vial and seal on arrival. Contact us about damage or an unexpected condition. Transport alone does not establish chemical stability or suitability for an experiment.

  3. 3Storage

    Follow the instructions supplied with the material and your laboratory’s validated procedure. Keep the vial sealed and protect it from moisture and light. Confirm product-specific temperature and shelf-life information before use.

  4. 4Laboratory solutions

    Solvent, pH, concentration and storage conditions depend on the material and assay. Use a validated laboratory protocol; a general mixing calculator does not establish compatibility, sterility or solution shelf life.

Documentation

No independent report is currently linked to this new strength.

Published papers are not certificates for this vial. Ask for the applicable analytical documentation; reports for another product or strength do not verify this listing.

Contact us · Certificate library

Frequently asked questions

What is supplied?

1 vial · 30 mg · Lyophilised powder. The stated milligrams describe total vial content, not a dose or the concentration of a prepared solution.

Documentation

No independent report is currently linked to this new strength. Published papers are not certificates for this vial. Ask for the applicable analytical documentation; reports for another product or strength do not verify this listing.

Can I order this strength now?

Yes. Select the quantity, add this vial to your cart or choose Buy now. Other vial strengths are listed separately.

How should I read the research?

The cited studies describe particular experimental materials and conditions. They do not test this supplied vial or establish its suitability for human or veterinary use.

Related research reading
Research & references

Description of Retatrutide (Reta)

Reta is the product name used here for retatrutide (LY3437943), an investigational synthetic peptide studied for activity at the GLP-1, GIP and glucagon receptors.

Overview of Published Research

The references below are background literature on retatrutide, including laboratory and clinical investigations. They do not describe testing of this product. Consult each publication for its study material, methods and limitations. This listing is the 30 mg vial; the named molecule and the limits of the cited evidence are unchanged by the vial size.

References

  1. Abdrabou Abouelmagd A, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proc (Bayl Univ Med Cent). 2025;38(3):291–303. doi: 10.1080/08998280.2025.2456441
  2. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247.e9. doi: 10.1016/j.cmet.2022.07.013
  3. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037–2048. doi: 10.1038/s41591-024-03018-2
  4. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. doi: 10.1056/NEJMoa2301972
  5. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544. doi: 10.1016/S0140-6736(23)01053-X
  6. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881. doi: 10.1016/S0140-6736(22)02033-5
Also in stock

Also in stock

All products →
Reta
In stock

Reta

€88.95

Reta 20 mg
In stock

Reta 20 mg

€168.95

Peptide Storage Case (10 vials)
In stock

Peptide Storage Case (10 vials)

€3.94